Gilead Sciences stock: HIV growth faces Biktarvy pricing risk
Published on 11/19/2026 at 16:41 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSWhat investors should watch
- HIV prevention is becoming a central growth pillar beyond Gilead's established treatment franchise.
- Pricing pressure on Biktarvy creates a long-term test for new product launches.
- The next key checkpoints are further Yeztugo adoption and the February 2027 reporting and regulatory calendar.
Gilead Sciences is trying to build its next growth phase beyond Biktarvy as future pricing pressure on the HIV treatment becomes clearer. In an analysis published Thursday, November 19, Trefis highlights HIV prevention as a key offset, while cautioning that the transition depends on sustained demand and successful launches.
Prevention becomes a growth test
According to the analysis, management said during the October 29 earnings call that Gilead's HIV prevention medicines were running at about 4 billion US dollars in annual sales. Yeztugo, the twice-yearly lenacapavir injection, generated 305 million US dollars in third-quarter sales, up 31 percent from the second quarter, and management expects roughly 1 billion US dollars for the full year.
Yeztugo and the prevention portion of Descovy together account for about half of the prevention market, Trefis writes. That gives Gilead a growing platform in HIV prevention, but the analysis also points to inventory effects and pricing as contributors to recent sales growth. If those effects fade, underlying demand will become more important.
Biktarvy remains the concentration risk
Biktarvy generated 14.3 billion US dollars of Gilead's 29.4 billion US dollars in total 2025 revenue. Trefis says management expects the lower Medicare price scheduled for 2028 to reduce Biktarvy revenue by about 1.5 billion US dollars, including related pressure from other US payers.
Management still expects total HIV revenue to grow in 2028 compared with 2027. That outlook requires prevention products and newer HIV medicines to add more revenue than Biktarvy loses. The analysis therefore frames Gilead's investment case around execution rather than a single product milestone.
Upcoming catalysts and risks
Gilead expects a regulatory decision in February 2027 on a once-weekly oral version of Yeztugo for prevention, while its next results are also expected around that time. Those updates should show whether prevention growth can continue after the inventory contribution diminishes.
The broader US market remains the backdrop for Gilead Sciences stock; Current market reports provide the wider equity context.
More news and analysis on Gilead Sciences stock.
Gilead Sciences company facts
- Company: Gilead Sciences, Inc.
- ISIN: US3755581036
- Ticker: GILD
- Primary listing: Nasdaq
